Remembering Sarah Harding and Advanced Breast Cancer

What Sarah Harding said

In August 2020, the Girls Aloud singer Sarah Harding said publicly that she had been diagnosed with breast cancer and that it had spread to other parts of her body. She was 38.

She published a memoir in March 2021. CBS News reported that she wrote about her illness in the hope that others would seek medical help rather than delay getting a diagnosis. She also disclosed that a doctor had told her she would likely not be alive the following Christmas.

Harding died in September 2021, at 39. Her mother announced it, writing that she "slipped away peacefully this morning."

That is the whole of the public record here. This article does not go past it, and it does not speculate about her care. What it can do is take her stated reason for writing seriously, because a delayed diagnosis in a woman under 40 involves a specific set of problems.

Nobody is screening a 38-year-old

The gap starts with a simple fact. Routine mammography does not apply to most women in their thirties.

The U.S. Preventive Services Task Force recommends screening mammography every two years for women aged 40 to 74. That is a grade B recommendation, issued April 30, 2024. Below 40, there is no general screening program.

That is not an oversight. Breast cancer becomes far more common with age. The National Cancer Institute states that the most important risk factor for breast cancer, besides female biological sex, is increasing age. SEER, the federal cancer statistics program, puts the median age at diagnosis at 64.

The consequence is worth stating plainly. For a woman in her twenties or thirties, symptoms are the entire detection system. There is no scan quietly checking in the background.

When to get checked

Because there is no safety net for younger women, this list carries more weight, not less. NCI says to contact a doctor about any of these:

• A lump, or a thick or firm area, in or near the breast or under the arm.
• A change in the size or shape of one breast.
• Nipple discharge that is not breast milk.
• A nipple that flattens, inverts, or changes the direction it points.
• Skin on the breast, nipple, or areola that becomes scaly, swollen, red, or darker.
• Dimpling, puckering, or a rash on the breast.
• Swelling of a whole breast, even with no lump at all.
• Itching or tingling in the nipple or areola.

Three points make that list usable:

NCI states that breast cancer does not usually cause pain. A painless lump is not a reassuring lump.

Breast tissue changes with the menstrual cycle, so a lump that comes and goes with your period behaves differently from one that stays. A lump still present after one full cycle should be examined, not watched for another six months.

Age is not a reason for anyone, including a clinician, to dismiss a persistent breast change. If a change persists and you have been reassured, going back is reasonable.

Who is at higher risk younger

NCI lists the risk factors that raise the odds. Inherited gene changes are the ones that shift the age curve most: harmful mutations in BRCA1, BRCA2, PALB2, CHEK2, TP53, CDH1, PTEN, STK11, and ATM.

For BRCA specifically, NCI's fact sheet puts lifetime breast cancer risk above 60% for people carrying a harmful change, against roughly 13% in the general population. NCI also puts lifetime ovarian cancer risk at about 39% to 58% with BRCA1 and 13% to 29% with BRCA2, against roughly 1.1% generally.

Other listed factors include a family history of breast cancer, especially in first-degree relatives, reproductive history that raises lifetime estrogen exposure, dense breast tissue, alcohol, excess body weight after menopause, inactivity after menopause, and radiation exposure, particularly at a young age.

Dense breasts do something twice over. NCI notes that dense tissue both increases risk and makes cancer harder to see on a mammogram.

A strong family history, or several relatives with breast or ovarian cancer, is a reason to ask about genetic counseling rather than simply waiting for age 40.

What "spread to other parts of the body" means

Harding disclosed that her cancer had spread. NCI describes stage IV breast cancer as cancer that has reached other parts of the body, such as the bones, liver, or lungs, and notes that this is also called metastatic breast cancer.

Two facts about that term help.

First, it is still breast cancer. Breast cancer that has settled in bone is not bone cancer, and it is treated with breast cancer drugs.

Second, treatment does not stop. It changes goal. Local treatment such as surgery and radiation targets one place, while systemic treatment travels through the bloodstream. NCI lists chemotherapy, hormone therapy, targeted therapy, and immunotherapy in that second group. The plan is built around controlling the disease and protecting quality of life over time, switching drugs when one stops holding.

Symptoms that suggest spread deserve fast attention in anyone with a breast cancer history. NCI names back pain, bone pain or fractures, shortness of breath, a constant dry cough, abdominal pain or swelling, jaundice, severe headaches, seizures, and vision changes.

What the numbers say about groups

These figures describe populations, not people.

The American Cancer Society projects 321,910 new female breast cancers in the United States in 2026, about 15.2% of all new cancer diagnoses, and 42,140 deaths; SEER reprints those projections. Five-year relative survival across all stages is 91.9% for women diagnosed from 2016 to 2022.

Stage changes that picture completely. Over the same 2016 to 2022 span, SEER records five-year relative survival of 100.0% for localized breast cancer, 87.5% for regional disease, and 33.8% once it has reached distant sites. About 64% of cases are found while localized, and about 6% are already distant at diagnosis.

NCI also gives the lifetime figure that puts individual risk in perspective: a woman has roughly a 1 in 8 chance, or 13 in 100, of developing breast cancer at some point.

None of these numbers describe any particular woman. They exist to show what stage at diagnosis is worth, which is exactly why Harding said she wrote about not delaying.

Sources

• NCI: Causes and Risk Factors for Breast Cancer
• NCI: Signs and Symptoms of Breast Cancer
• NCI: Breast Cancer Stages
• NCI: Treatment for Breast Cancer
• NCI: BRCA Gene Changes — Cancer Risk and Genetic Testing Fact Sheet
• SEER Cancer Stat Facts: Female Breast Cancer
• USPSTF: Breast Cancer Screening, final recommendation, April 30, 2024
• CBS News: Sarah Harding, singer of British pop group Girls Aloud, dies at 39 after battle with breast cancer